Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid PolyarthritisCTRL COHNCT05370079
Control Cohort CTRL COH
A study testing Collection of biological sample (blood and/or CSF) in people with Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis, run by Hospices Civils de Lyon at 1 site in France.
Trial summary
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis
- What is being tested?
- Collection of biological sample (blood and/or CSF)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 350 participants
- Where
- 1 siteFrance
- Study dates
- 8 Aug 2023to 8 Aug 2028
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- patient with consent
- patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Who cannot join
- refusal consent
- patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
- patient under guardianship
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site, 1 recruiting
- Recruiting
Hospices Civils de Lyon
Bron, 69500
Jerome HONNORAT, Pr, (33) 4 72 35 78 06, jerome.honnorat@chu-lyon.fr
Jerome HONNORAT
About this study
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.
- Being tested
- Collection of biological sample (blood and/or CSF)
- Keywords
- Biological collection, control cohort,, new biomarkers
- Medical subject headings
- Parkinson Disease, Amyotrophic Lateral Sclerosis, Glioblastoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Collection of biological sample (blood and/or CSF)Biological
Blood sample will be collected one time for each patient:
2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube
If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).
| Study group | Role | What they receive |
|---|---|---|
| Control cohort | Other | Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis. Receives: Biological: Collection of biological sample (blood and/or CSF) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid)
Numbers of samples collected and patients included in the cohort
Measured: 15 minutes
Secondary outcomes (1)
Description of genetic analysis
Number of new biomarkers (genetic) and specific HLA (human leucocyte antigen)
Measured: Data collecting: 3 years Data analysis: 2 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 May 2022
- Study start8 Aug 2023
- Primary completion8 Aug 2028 (estimated)
- Study completion8 Aug 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid PolyarthritisStudies of the same condition, open and under way.
- More trials run by Hospices Civils de LyonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 350 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Hospices Civils de Lyon
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Jerome Honnorat, Pr, Principal investigator, Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, France
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05370079
- Sponsor's protocol ID
- 69HCL22_0275
- Acronym
- CTRL COH
- Status last verified
- Jan 2026
- First submitted
- 6 May 2022
- Last updated
- 15 Jan 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Control Cohort CTRL COH
- ClinicalTrials.gov ID
- NCT05370079
- Acronym / sponsor ID
- CTRL COH / 69HCL22_0275
- Keywords
- Biological collection, control cohort,, new biomarkers
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 350 participants (estimated)
- Lead sponsor
- Hospices Civils de LyonUniversity, hospital or other
- Study start
- 8 Aug 2023 (actual)
- Primary completion
- 8 Aug 2028 (estimated)
- Study completion
- 8 Aug 2028 (estimated)
- First posted
- 11 May 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Autoimmune encephalitis (AE) and paraneoplastic neurological syndromes (PNS) are rare disease that could be difficult to diagnose. So it necessary to obtain numerous sample from different disease to develop more specific diagnosis kit It could be possible through the characterisation of new genetic biomarkers.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Control cohort | Other | Biological: Collection of biological sample (blood and/or CSF)Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- patient with consent
- patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Key exclusion criteria (3 listed)
- refusal consent
- patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
- patient under guardianship
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Collection of biological sample (blood and/or CSF)Blood sample will be collected one time for each patient: 2 *4ml of blood on dry tube 2 *4ml of blood on EDTA tube If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml). | Biological | Control cohort |
Primary outcome
Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid)
Time frame: 15 minutes
Numbers of samples collected and patients included in the cohort
1 secondary outcome
Description of genetic analysis
Time frame: Data collecting: 3 years Data analysis: 2 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2026.
- Individual participant dataSharing planned: No
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jerome Honnorat, Pr principal investigator
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, France
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Collection of biological sample (blood and/or CSF) in people with Parkinson's Disease; Amyotrophic Lateral Sclerosis; Glioblastoma; Cancer Without Neurological Disease; Rheumatoid Polyarthritis, run by Hospices Civils de Lyon at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 15 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jerome Honnorat, Pr ((33) 4 72 35 78 06, jerome.honnorat@chu-lyon.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Samples (blood dry and EDTA tube and optional cerebro-spinal-fluid) (time frame: 15 minutes). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2026.